AVITA Medical Reports Positive PermeaDerm Study Results
VALENCIA, Calif., August 18, 2026 AVITA Medical, Inc. announced positive results from the multicenter, randomized controlled PermeaDerm-I clinical study,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
VALENCIA, Calif., August 18, 2026 AVITA Medical, Inc. announced positive results from the multicenter, randomized controlled PermeaDerm-I clinical study,...
VALENCIA, Calif., June 18, 2026 AVITA Medical, Inc. announced positive first U.K. clinical experience with its RECELL GO® automated...
VALENCIA, Calif., April 29, 2026 AVITA Medical, Inc. has announced that its next-generation wound care platform RECELL GO® has...
